Ohio State is in the process of revising websites and program materials to accurately reflect compliance with the law. While this work occurs, language referencing protected class status or other activities prohibited by Ohio Senate Bill 1 may still appear in some places. However, all programs and activities are being administered in compliance with federal and state law.

Outcomes

MBTP started in 2017 with an initial NIH T32 grant award.  It was continued in 2022 with a second award.  There have been 31 trainees (both NIH-funded and matched positions) between 2017-2024.  This has resulted in 8 Ph.D.'s and 2 M.S.'s (18 students are still in graduate training).

Our trainees have gone on to a variety of positions in academia, biotechnology, and the pharmaceutical industry.  Three did academic or government (NIH) postdoctoral training as their first position.  They work in a variety of places, including Curia, CAS, Celerion, Moderna, and Procter & Gamble.